Background: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD). Objective:We sought to characterize the relationship betweenAβ and tau ligands as well as with other measures of pathology. Methods: We conducted a multi-center observational study in early AD (MMSE > 20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of A- and tau at baseline and 6 months; PET-CT imaging with Aβ ([18F]AV45) and tau ([18F]AV1451) ligands at baseline. Results: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical Aβ associated with entorhinal cortex tau while CSF tau/Aβ ratio correlated strongly with cortical tau but not Aβ Conclusion: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker'the CSF total tau/Aβ ratio.

PET tau and amyloid-β burden in mild Alzheimer's disease: Divergent relationship with age, cognition, and cerebrospinal fluid biomarkers / Koychev, Ivan; Gunn, Roger N.; Firouzian, Azadeh; Lawson, Jennifer; Zamboni, Giovanna; Ridha, Basil; Sahakian, Barbara J.; Rowe, James B.; Thomas, Alan; Rochester, Lynn; Ffytche, Dominic; Howard, Robert; Zetterberg, Henrik; Mackay, Clare; Lovestone, Simon. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - 60:1(2017), pp. 283-293. [10.3233/JAD-170129]

PET tau and amyloid-β burden in mild Alzheimer's disease: Divergent relationship with age, cognition, and cerebrospinal fluid biomarkers

Zamboni, Giovanna;Thomas, Alan;
2017

Abstract

Background: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD). Objective:We sought to characterize the relationship betweenAβ and tau ligands as well as with other measures of pathology. Methods: We conducted a multi-center observational study in early AD (MMSE > 20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of A- and tau at baseline and 6 months; PET-CT imaging with Aβ ([18F]AV45) and tau ([18F]AV1451) ligands at baseline. Results: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical Aβ associated with entorhinal cortex tau while CSF tau/Aβ ratio correlated strongly with cortical tau but not Aβ Conclusion: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker'the CSF total tau/Aβ ratio.
2017
60
1
283
293
PET tau and amyloid-β burden in mild Alzheimer's disease: Divergent relationship with age, cognition, and cerebrospinal fluid biomarkers / Koychev, Ivan; Gunn, Roger N.; Firouzian, Azadeh; Lawson, Jennifer; Zamboni, Giovanna; Ridha, Basil; Sahakian, Barbara J.; Rowe, James B.; Thomas, Alan; Rochester, Lynn; Ffytche, Dominic; Howard, Robert; Zetterberg, Henrik; Mackay, Clare; Lovestone, Simon. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - 60:1(2017), pp. 283-293. [10.3233/JAD-170129]
Koychev, Ivan; Gunn, Roger N.; Firouzian, Azadeh; Lawson, Jennifer; Zamboni, Giovanna; Ridha, Basil; Sahakian, Barbara J.; Rowe, James B.; Thomas, Alan; Rochester, Lynn; Ffytche, Dominic; Howard, Robert; Zetterberg, Henrik; Mackay, Clare; Lovestone, Simon
File in questo prodotto:
File Dimensione Formato  
Koychev2017_JAD.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 963.95 kB
Formato Adobe PDF
963.95 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1152726
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 54
social impact